The biology of Hodgkin's lymphoma

By Ralf Küppers. Nature Reviews. Cancer, 2009

747 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/1adba0a5f0b4744fd3320649a53ae15fb93217c6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Michael R. Green

In Oncology

1. K. Munger
2. M. Feitelson
3. E. Mesri

Citations in the corpus

• Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. (2017, neutral): “9) 0 0 Nasopharyngitis 19 (9) 0 0 2 (1) 0 0 Dyspnea 18 (8.”
• HUMAN VIRAL ONCOGENESIS: A CANCER HALLMARKS ANALYSIS (2014, background): “They are derived from germinal B-cells destined to undergo apoptosis that are protected by EBV Lat II genes LMP-1 and LMP-2 (Kuppers, 2009).”
• Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Post-transplant Lymphoproliferative Disorders: Implications for Targeted Therapy (2012, background): “Epstein–Barr virus (EBV) has been implicated in approximately 40% of cHLs (1) and in additional B-cell disorders such as posttransplant lymphoproliferative disorders (PTLD) that occur in the setting of host immunosuppression (2).”